T-lymphocyte surface Cluster of Differentiation antigens (T-cell CD antigens)

T-lymphocyte surface Cluster of Differentiation (CD) antigens are a broad category of cell surface molecules used to identify and characterize the various stages of T-cell development and activation (StatPearls: NBK554473). This group includes essential proteins such as the CD3 complex, which is required for T-cell receptor signaling, and the co-receptors CD4 and CD8, which facilitate interaction with MHC class II and class I molecules, respectively (UniProt: P07766; NIH: PMC4747096). These antigens play a pivotal role in the adaptive immune system by regulating signal transduction and cell-to-cell adhesion during the immune response. In the context of drug development, individual CD antigens serve as critical therapeutic targets for treating hematological malignancies, autoimmune disorders, and preventing organ transplant rejection. For example, monoclonal antibodies like Teplizumab target CD3 to delay the onset of Type 1 diabetes, while bispecific antibodies like Blinatumomab utilize CD3 to engage T-cells against B-cell cancers (FDA: Drugs@FDA). However, because these antigens are central to immune function, therapies targeting them often carry significant risks, including cytokine release syndrome and profound, long-lasting immunosuppression.

Other names

T-cell surface markersT-cell CD markersCluster of Differentiation antigens on T-lymphocytesT-lymphocyte antigens

Modulation of T-cell receptor signaling, induction of T-cell depletion, blockade of co-stimulatory pathways, or redirection of T-cell cytotoxicity against specific target cells (StatPearls: NBK554473).